BPC-157 + TB-500 Synergy
Overview
Pairing BPC-157 with TB-500 (Thymosin Beta-4 / Ac-SDKP) is a complementary-peptide strategy studied in regenerative research. The two act through different but overlapping routes — BPC-157 chiefly via nitric-oxide modulation and angiogenic growth-factor signalling, TB-500 via actin sequestration and cell migration — so the combination is investigated as a broader repair stimulus than either alone. This page compares the two and summarises the research rationale for using them together.
Overview
The two peptides address different parts of the repair process. The table below summarises how they are usually positioned relative to each other.
| Peptide | Primary mechanism | Tissue focus |
|---|---|---|
| BPC-157 | NO modulation, VEGF/FGF upregulation, gastroprotection | GI tract, tendon, nerve |
| TB-500 (Ac-SDKP) | Actin sequestration, angiogenesis, ECM remodeling | Muscle, skin, cardiac |
| Combination | Complementary angiogenic + cytoprotective | Multi-tissue repair research |
Mechanisms of Synergy
Complementary angiogenesis
BPC-157 is studied for raising VEGF/FGF via NO-dependent routes, while TB-500 is studied for directly promoting endothelial-cell migration — two different angles on new-vessel formation.
Coordinated cell migration
BPC-157 is linked to fibroblast/keratinocyte migration; TB-500 supplies the actin dynamics cells need to move — together studied for more efficient wound repopulation.
Balanced inflammation
Both are reported to lower pro-inflammatory cytokines and support anti-inflammatory mediators, studied for resolving the inflammatory phase without over-suppressing it.
Matrix remodeling
BPC-157 is associated with collagen synthesis and TB-500 with MMP modulation — a combination framed around scar quality and tensile strength.
Comparative Properties
| Property | BPC-157 | TB-500 (Ac-SDKP) |
|---|---|---|
| Molecular weight | 1419.5 Da | 500.5 Da |
| Amino acids | 15 | 4 (active fragment) |
| Half-life | ≈ 15 min (plasma) | ≈ 2–6 h |
| Character | Hydrophilic (logP −2.8) | Hydrophilic (logP −3.1) |
| Primary mechanism | NO modulation, VEGF/FGF | Actin sequestration, migration |
| Stability (lyophilized) | ≥ 24 months at −20°C | ≥ 24 months at −20°C |
Synthesis Pathway Comparison
Both peptides are made separately by Fmoc solid-phase peptide synthesis and purified to research grade; TB-500 (Ac-SDKP) additionally carries an N-terminal acetyl group.
| Parameter | BPC-157 | TB-500 (Ac-SDKP) |
|---|---|---|
| Method | Fmoc-SPPS | Fmoc-SPPS |
| Resin | Rink amide MBHA | Rink amide MBHA |
| N-terminal modification | Free amine | Acetylated (Ac) |
| Amino acids | 15 residues | 4 residues (active fragment) |
| Coupling | HBTU / HOBt / DIPEA | HBTU / HOBt / DIPEA |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative RP-HPLC (C18) | Preparative RP-HPLC (C18) |
| Salt form | Trifluoroacetate / chloride | Trifluoroacetate / chloride |
Stability & Compatibility
The two peptides have different degradation kinetics, so the usual research recommendation is to reconstitute and store them separately.
| Parameter | Guidance |
|---|---|
| Storage form | Store each peptide separately in sealed vials at −20°C |
| Co-formulation | Not recommended in the same vial (different kinetics) |
| Combining | If co-injection is intended, combine only immediately before use |
| Administration | Best given as separate injections at different sites |
| pH compatibility | Both work near pH 5.5–6.5 — compatible range |
| Freeze–thaw | Limit to ~3 cycles; aliquot if needed |
Research Evidence
Combination research is mostly at the animal-model stage. Representative models and their focus are named below; specific numerical outcomes are not restated here as claims.
| Model | Research focus |
|---|---|
| Rodent skin-excision wound | Combined vs single-peptide wound closure |
| Rat Achilles-tendon transection | Functional and histological tendon recovery |
| Rat muscle-crush injury | Muscle-fiber regeneration and fibrosis |
| Murine full-thickness burn | Epithelialization rate |
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
Research Combination Protocol
Reconstitution-oriented reference from the literature; not human dosing guidance.
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Individual research dose | ≈ 250–500 µg | ≈ 2.5–5 mg |
| Frequency | Daily (study protocols) | ≈ every 72 h |
| Route | Subcutaneous | Subcutaneous (separate site) |
| Reconstitution | Bacteriostatic water | Bacteriostatic water |
Safety (Combination)
Both peptides are individually reported as well tolerated in animal studies, with no specific interaction documented; the combination is nonetheless for research use only, not for human or veterinary use.
- Administer as separate injections at different sites rather than mixing in one vial.
- Follow the same handling and storage precautions as for each peptide alone.
Selected References
- Sikiric P, et al. BPC-157 tissue-repair literature (review and preclinical studies).
- Malinda KM, et al. Thymosin beta-4 accelerates wound healing. Journal of Investigative Dermatology, 1999.
- Goldstein AL, Kleinman HK. Advances in the applications of thymosin beta-4 (review literature).
Quality & Supply
- Both peptides available research-grade, HPLC-characterized with a Certificate of Analysis
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Supplied as separate vials for flexible research protocols
Need BPC-157 + TB-500 Synergy — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
